Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Instead of IPO, Aptalis takes $2.9bn acquisition offer from Forest Laboratories

Executive Summary

Less than two weeks after filing an S-1 to go public, private spec pharma Aptalis Holdings Inc. scrapped those plans and instead agreed to be acquired by Forest Laboratories Inc. for $2.9bn in cash.
Deal Industry
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Full Acquisition

Related Companies

UsernamePublicRestriction

Register